PHK
LYEL icon

Point72 Hong Kong’s Lyell Immunopharma LYEL Stock Holding History

Point72 Hong Kong’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-675
Closed -$68K – 2216
2022
Q1 		$68K Buy
+675
New +$81.8K ﹤0.01% 1258
2021
Q3 		– Sell
-1,420
Closed -$461K – 2250
2021
Q2 		$461K Buy
+1,420
New +$466K 0.02% 947

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Hong Kong's LYEL Position: Q2 2022 in Review

Point72 Hong Kong sold out of Lyell Immunopharma (LYEL) in Q2 2022, closing a stake of 675 shares — an estimated $68K sold.

Point72 Hong Kong first reported a position in LYEL in Q2 2021 and held it in 2 quarters. The position peaked at $461K in Q2 2021. 75 funds tracked by Wall St. Rank hold LYEL as of Q2 2022.

  • Point72 Hong Kong reported no remaining Lyell Immunopharma position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 675 Lyell Immunopharma shares in Q2 2022, an estimated $68K.
  • Point72 Hong Kong first reported a position in Lyell Immunopharma in Q2 2021 and held it in 2 quarters.
  • Point72 Hong Kong's Lyell Immunopharma position peaked at $461K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.